GPR55 and myeloid sarcoma: Since inflammation is one of the hallmarks of neurodegenerative diseases, targeting GPR55 might be a novel therapeutic approach for the treatment of neurodegenerative diseases like PD, AD, and MS (Saliba et al., 2018).